| Dr Andre P Lallande, DO | |
|
5726 Ridgemark Pl, Fontana, CA 92336-5159 | |
| (909) 559-1050 | |
| Not Available |
| Full Name | Dr Andre P Lallande |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 29 Years |
| Location | 5726 Ridgemark Pl, Fontana, California |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053471045 | NPI | - | NPPES |
| 05D0575313 | Other | CA | CLIA # FOR GROUP |
| ZZZ34392Z | Other | CA | MEDICARE GROUP ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 20A7021 (California) | Secondary |
| 207RR0500X | Internal Medicine - Rheumatology | 20A7021 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventist Health Clearlake | Clearlake, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lake County Tribal Health Consortium Inc | 8729975545 | 25 |
News Archive
Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced results from its recently completed Phase 1 clinical trial evaluating the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure.
As the COVID-19 pandemic continues, many children have returned to school in-person this year for the first time in 18 months.
For about 90 percent of men with prostate cancer, the cancer remains localized to the primary site, resulting in a five-year survival rate of almost 100 percent.
Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy-harnessing the immune system in medical treatments. In cell cultures and animal models, a potent drug attached to an antibody selectively zeroes in on cancer cells without harming healthy cells.
A new state report shows the average Oregon hospital more than doubled its margin, or profit, between 2009 and 2011, even as its provision of charity care went down. The findings trace the hospital sector rebound from recessionary lows in 2008, and how expanded Medicaid enrollment in Oregon has helped boost hospitals' bottom line even as many continue to expand to some assessors' dismay (Budnick, 7/5).
› Verified 3 days ago
| Entity Name | Lake County Tribal Health Consortium Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881697381 PECOS PAC ID: 8729975545 Enrollment ID: O20040304000323 |
News Archive
Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced results from its recently completed Phase 1 clinical trial evaluating the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure.
As the COVID-19 pandemic continues, many children have returned to school in-person this year for the first time in 18 months.
For about 90 percent of men with prostate cancer, the cancer remains localized to the primary site, resulting in a five-year survival rate of almost 100 percent.
Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy-harnessing the immune system in medical treatments. In cell cultures and animal models, a potent drug attached to an antibody selectively zeroes in on cancer cells without harming healthy cells.
A new state report shows the average Oregon hospital more than doubled its margin, or profit, between 2009 and 2011, even as its provision of charity care went down. The findings trace the hospital sector rebound from recessionary lows in 2008, and how expanded Medicaid enrollment in Oregon has helped boost hospitals' bottom line even as many continue to expand to some assessors' dismay (Budnick, 7/5).
› Verified 3 days ago
| Entity Name | Arthritis Center Of Riverside Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013076850 PECOS PAC ID: 4981775319 Enrollment ID: O20080612000488 |
News Archive
Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced results from its recently completed Phase 1 clinical trial evaluating the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure.
As the COVID-19 pandemic continues, many children have returned to school in-person this year for the first time in 18 months.
For about 90 percent of men with prostate cancer, the cancer remains localized to the primary site, resulting in a five-year survival rate of almost 100 percent.
Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy-harnessing the immune system in medical treatments. In cell cultures and animal models, a potent drug attached to an antibody selectively zeroes in on cancer cells without harming healthy cells.
A new state report shows the average Oregon hospital more than doubled its margin, or profit, between 2009 and 2011, even as its provision of charity care went down. The findings trace the hospital sector rebound from recessionary lows in 2008, and how expanded Medicaid enrollment in Oregon has helped boost hospitals' bottom line even as many continue to expand to some assessors' dismay (Budnick, 7/5).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andre P Lallande, DO 5726 Ridgemark Pl, Fontana, CA 92336-5159 Ph: (909) 559-1050 | Dr Andre P Lallande, DO 5726 Ridgemark Pl, Fontana, CA 92336-5159 Ph: (909) 559-1050 |
News Archive
Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced results from its recently completed Phase 1 clinical trial evaluating the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure.
As the COVID-19 pandemic continues, many children have returned to school in-person this year for the first time in 18 months.
For about 90 percent of men with prostate cancer, the cancer remains localized to the primary site, resulting in a five-year survival rate of almost 100 percent.
Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy-harnessing the immune system in medical treatments. In cell cultures and animal models, a potent drug attached to an antibody selectively zeroes in on cancer cells without harming healthy cells.
A new state report shows the average Oregon hospital more than doubled its margin, or profit, between 2009 and 2011, even as its provision of charity care went down. The findings trace the hospital sector rebound from recessionary lows in 2008, and how expanded Medicaid enrollment in Oregon has helped boost hospitals' bottom line even as many continue to expand to some assessors' dismay (Budnick, 7/5).
› Verified 3 days ago
Nainesh K. Gandhi, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 9985 Sierra Ave, Fontana, CA 92335 Phone: 866-454-3485 | |
Blanca E. Viramontes, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
Dr. Paymon Mesgarzadeh, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 9985 Sierra Ave, Fontana, CA 92335 Phone: 909-427-5000 | |
Kathryn Chang Lin, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 16465 Sierra Lakes Pkwy, Ste 245, Fontana, CA 92336 Phone: 909-829-7337 Fax: 909-829-1218 | |
Lih-jiau Chen, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
Tommy Tiong Hien Oei, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
Edmond C. Hui, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 |